Hunan Fangsheng Pharmaceutical (603998.SH) plans to acquire the marketing approval for the "Xiaoqinglong Capsule" medication.

Hunan Fangsheng Pharmaceutical (603998.SH) announced that on February 25, 2025, the company has signed a "Drug Listing Permit Transfer Agreement" with Noticon Bio, acquiring the drug listing permit for "Xiaoqinglong Capsules." Xiaoqinglong Capsules have the effects of resolving exterior pathogens, stopping cough, and alleviating asthma. They are used for wind-cold water retention, aversion to cold and fever, no sweating, cough with thin sputum.